Marco Weinberg

Marco Weinberg is an accomplished leader in gene therapy and molecular biology with extensive experience in research and development. Currently serving as Senior Vice President and Head of Research at ReCode Therapeutics since August 2023, Marco previously held the position of Vice President of R&D Gene Editing at Asklepios BioPharmaceutical, Inc., where significant advancements in therapeutic gene editing and collaborations were achieved. Additional roles include Director of Gene Therapy Research at CSL Behring and Associate Director at Vertex Pharmaceuticals, where Marco led initiatives in gene editing and nucleic acid therapies. With a solid academic background including a PhD from the University of the Witwatersrand and various faculty positions, Marco's contributions to RNA therapies and gene editing have established a strong foundation in the field of therapeutics.